libtherapeutics.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | LIB |
| Description | Our objective is to help patients achieve their goal, where lower is About Us LDL-C, CVD & PCSK9 Pipeline News & Events Contact About Us LDL-C, CVD & PCSK9 Pipeline News & Events Contact Our objective is to help patients ac |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 75.2.70.75 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
libtherapeutics.com Valuation
|
US$1,005
Last updated: 2023-05-20 05:26:12
libtherapeutics.com has Semrush global rank of 0. libtherapeutics.com has an estimated worth of US$ 1,005, based on its estimated Ads revenue. libtherapeutics.com receives approximately 116 unique visitors each day. Its web server is located in United States, with IP address 75.2.70.75. According to SiteAdvisor, libtherapeutics.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$1,005 |
| Daily Ads Revenue | US$0 |
| Monthly Ads Revenue | US$27 |
| Yearly Ads Revenue | US$334 |
| Daily Unique Visitors | 7 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| libtherapeutics.com. | A | 1799 | IP: 75.2.70.75 |
| libtherapeutics.com. | A | 1799 | IP: 99.83.190.102 |
| libtherapeutics.com. | NS | 86400 | NS Record: ns3.bdm.microsoftonline.com. |
| libtherapeutics.com. | NS | 86400 | NS Record: ns4.bdm.microsoftonline.com. |
| libtherapeutics.com. | NS | 86400 | NS Record: ns1.bdm.microsoftonline.com. |
| libtherapeutics.com. | NS | 86400 | NS Record: ns2.bdm.microsoftonline.com. |
| libtherapeutics.com. | MX | 3600 | MX Record: 0 libtherapeutics-com.mail.protection.outlook.com. |
| libtherapeutics.com. | TXT | 3600 | TXT Record: mscid=ZR+52aLSPNQ2rJdCiTi522vqF+tHUB4o6Yiy3uEIB+DW0SZHYhOgpfpuD7so9KYykOEFgLvk3XjLkNeBQXPWnw== |
| libtherapeutics.com. | TXT | 3600 | TXT Record: v=spf1 include:spf.protection.outlook.com -all |
HtmlToTextCheckTime:2023-05-20 05:26:12
| About Us LDL-C, CVD & PCSK9 Pipeline News & Events Contact About Us LDL-C, CVD & PCSK9 Pipeline News & Events Contact Our objective is to help patients achieve their goal, where lower is better. Developing best-in-class injectable and oral PCSK9 inhibitors for LDL cholesterol reduction and CVD prevention About Us LDL-C, CVD & PCSK9 Pipeline News & Events Contact About us Background LIB Therapeutics was founded in 2015 by Drs. Evan Stein and August Troendle as a private, self-funded company with assets from BMS. The LIB model is totally virtual, highly flexible, and designed to move through all phases of development and regulatory as quickly and smoothly as possible. This has enabled LIB to develop and optimize manufacturing of its lead asset, lerodalcibep (LIB003), complete all preclinical toxicology, phase 1, phase 2 dose selection, a 52-week phase 2b trials, and initiate and enroll 7 large global phase 3 trials in under 6 years. Our compounds As a late stage clinical |
HTTP Headers
HTTP/1.1 301 Moved Permanently Date: Thu, 12 Jan 2023 09:14:43 GMT Content-Type: text/html Content-Length: 166 Connection: keep-alive Location: https://libtherapeutics.com/ HTTP/2 301 date: Thu, 12 Jan 2023 09:14:44 GMT content-type: text/html content-length: 166 location: https://www.libtherapeutics.com/ HTTP/2 200 date: Thu, 12 Jan 2023 09:14:44 GMT content-type: text/html content-length: 73597 accept-ranges: bytes age: 0 x-served-by: cache-iad-kiad7000057-IAD, cache-dub4342-DUB x-cache: MISS, MISS x-cache-hits: 0, 0 x-timer: S1673514884.227452,VS0,VE267 vary: Accept-Encoding,x-wf-forwarded-proto x-cluster-name: eu-west-1-prod-edge-blue |